Phase 1
N=96
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Obesity
Bottom Line
View on ClinicalTrials.gov: NCT04779697 ↗Enrolled (actual)
96
Serious AEs
1.0%
Results posted
Feb 2026
Primary outcome: Primary: Change in Craving Score — -0.7; -0.3 score — p=< 0.001
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- GLP-1 analogue - semaglutide (Drug); Placebo (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Yale University
- Primary completion
- Nov 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Craving Score |
-0.7; -0.3 | < 0.001 sig |
| PRIMARY Change in Hunger Score |
-0.5; -0.1 | > 0.27 |
| PRIMARY Change in Food Intake |
-0.4; 0.4 | < 0.043 sig |
| SECONDARY Change in Food Intake - Real-World |
-485.7; -124.5 | < 0.015 sig |
| SECONDARY Change in Stress Score |
-2.8; -1.7 | > 0.53 |
Summary
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
Eligibility Criteria
Inclusion Criteria
- BMI ranging from 30-49.9 kg/m2
- No significant medical problems, including diabetes
- No history of HgbA1c 10% of total body weight during the prior 6 months
- Taking any other anti-obesity medication
- History of pancreatitis, medullary thyroid cancer, or MEN syndrome, or (6) women who are pregnant or lactating, or peri/postmenopausal
Data sourced from ClinicalTrials.gov (NCT04779697). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.